Clinical Trials Directory

Trials / Completed

CompletedNCT01891812

Nitrous Oxide Analgesia Vaso-occlusive Crisis

Nitrous Oxide for Analgesia in Sickle Cell Vaso-occlusive Crisis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
5 (actual)
Sponsor
Columbia University · Academic / Other
Sex
All
Age
8 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Patients who have sickle cell VOC are usually treated with opioids, such as morphine. However, this current way of treating them has not improved the health, medical outcomes, or rates of hospitalizations. In addition, since VOC can happen very frequently over a long period of time, giving opioids over and over again can cause both short-term and long-term problems. Nitrous oxide (N2O) is a way of treating pain that may provide a better alternative to repeatedly giving opioids over long periods of time. N2O has been shown to provide up to 3 hours of pain relief in inpatient patients with VOC whose pain did not improve with morphine infusions, and is used extensively in France, where almost half of 85 pediatric emergency departments use nitrous oxide to treat children with VOC whose pain did not get better with standard treatment with morphine. However, pain relief which N2O provides in the acute setting has not been well described. Therefore, the purpose of our study is to describe how well N2O can relieve the pain in patients with SCD who present to the emergency department and are experiencing a VOC.

Conditions

Interventions

TypeNameDescription
DRUGNitrous oxide 50%

Timeline

Start date
2013-11-12
Primary completion
2018-01-19
Completion
2018-01-19
First posted
2013-07-03
Last updated
2026-01-28
Results posted
2024-07-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01891812. Inclusion in this directory is not an endorsement.